Matches in SemOpenAlex for { <https://semopenalex.org/work/W4251819462> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W4251819462 endingPage "iii14" @default.
- W4251819462 startingPage "iii13" @default.
- W4251819462 abstract "Background: Patients (pts) with rGBM have a poor prognosis. EGFRamp is present in ~50% of GBMs. ABT-414 is an ADC that releases a potent toxin, monomethyl auristatin F (MMAF), inside cells with EGFRamp. Here we report the safety and efficacy of ABT-414 monotherapy at the recommended phase 2 dose (RPTD) in EGFRamp, rGBM. Methods: M12-356 (NCT01800695) is an open-label, Phase 1 study with three escalation cohorts. Study design and RPTD was reported previously (ASCO Meeting 2015, SNO Meeting 2015). Sixty pts, all with EGFRamp, rGBM, were enrolled as part of the escalation (12 pts) or expansion (48 pts) cohort treated with ABT-414 monotherapy at 1.25 mg/kg. Adults with measurable (RANO), bevacizumab-naïve, rGBMs with EGFRamp confirmed centrally were eligible. Results: As of March 1, 2016, 60 pts with EGFRamp, rGBM underwent treatment. Median age was 58 years (range, 35–80). Pts underwent 1, 2 (43% each) or 3 (13%) prior therapies. The most common treatment emergent adverse events (TEAEs) (≥20% pts) included blurred vision (65%), headache, fatigue (30% each), eye pain and photophobia (28% each). Grade 3/4 TEAEs (>1 pt) were keratitis (13%), corneal epithelial microcysts (8%), blurred vision (5%), dry eye, ulcerative keratitis and reduced visual acuity (3% each). The best RANO responses of 56 pts with complete data were: 3 (5%) partial responses, 24 (43%) stable diseases and 29 (52%) progressive diseases. Median duration of overall response in 3 patients with partial responses was 4.4 months (range, 1.9–5.6). The 6-month progression-free survival (PFS6) estimate was 25.3% [95% CI=14.8, 37.2]. Conclusions: ABT-414 monotherapy displayed frequent but mostly grade 1/2 ocular toxicities. An encouraging PFS6 (25%) was observed in this rGBM population where 56% had ≥2 prior therapies. A global randomized trial of ABT-414, alone or with TMZ, vs. TMZ or lomustine, is underway in EGFRamp, rGBM (NCT02343406)." @default.
- W4251819462 created "2022-05-12" @default.
- W4251819462 creator A5002987297 @default.
- W4251819462 creator A5010378038 @default.
- W4251819462 creator A5043283062 @default.
- W4251819462 creator A5059093147 @default.
- W4251819462 creator A5059965175 @default.
- W4251819462 creator A5062971193 @default.
- W4251819462 creator A5076107697 @default.
- W4251819462 creator A5086283695 @default.
- W4251819462 creator A5090305344 @default.
- W4251819462 date "2017-04-01" @default.
- W4251819462 modified "2023-10-01" @default.
- W4251819462 title "OS07.4 Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, as monotherapy in epidermal growth factor receptor (EGFR) amplified (EGFRamp), recurrent glioblastoma (rGBM)" @default.
- W4251819462 doi "https://doi.org/10.1093/neuonc/nox036.045" @default.
- W4251819462 hasPublicationYear "2017" @default.
- W4251819462 type Work @default.
- W4251819462 citedByCount "3" @default.
- W4251819462 countsByYear W42518194622017 @default.
- W4251819462 countsByYear W42518194622018 @default.
- W4251819462 countsByYear W42518194622020 @default.
- W4251819462 crossrefType "journal-article" @default.
- W4251819462 hasAuthorship W4251819462A5002987297 @default.
- W4251819462 hasAuthorship W4251819462A5010378038 @default.
- W4251819462 hasAuthorship W4251819462A5043283062 @default.
- W4251819462 hasAuthorship W4251819462A5059093147 @default.
- W4251819462 hasAuthorship W4251819462A5059965175 @default.
- W4251819462 hasAuthorship W4251819462A5062971193 @default.
- W4251819462 hasAuthorship W4251819462A5076107697 @default.
- W4251819462 hasAuthorship W4251819462A5086283695 @default.
- W4251819462 hasAuthorship W4251819462A5090305344 @default.
- W4251819462 hasBestOaLocation W42518194621 @default.
- W4251819462 hasConcept C126322002 @default.
- W4251819462 hasConcept C141071460 @default.
- W4251819462 hasConcept C143998085 @default.
- W4251819462 hasConcept C197934379 @default.
- W4251819462 hasConcept C2776694085 @default.
- W4251819462 hasConcept C2777802072 @default.
- W4251819462 hasConcept C2779159986 @default.
- W4251819462 hasConcept C2780590625 @default.
- W4251819462 hasConcept C29730261 @default.
- W4251819462 hasConcept C31760486 @default.
- W4251819462 hasConcept C71924100 @default.
- W4251819462 hasConcept C90924648 @default.
- W4251819462 hasConceptScore W4251819462C126322002 @default.
- W4251819462 hasConceptScore W4251819462C141071460 @default.
- W4251819462 hasConceptScore W4251819462C143998085 @default.
- W4251819462 hasConceptScore W4251819462C197934379 @default.
- W4251819462 hasConceptScore W4251819462C2776694085 @default.
- W4251819462 hasConceptScore W4251819462C2777802072 @default.
- W4251819462 hasConceptScore W4251819462C2779159986 @default.
- W4251819462 hasConceptScore W4251819462C2780590625 @default.
- W4251819462 hasConceptScore W4251819462C29730261 @default.
- W4251819462 hasConceptScore W4251819462C31760486 @default.
- W4251819462 hasConceptScore W4251819462C71924100 @default.
- W4251819462 hasConceptScore W4251819462C90924648 @default.
- W4251819462 hasIssue "suppl_3" @default.
- W4251819462 hasLocation W42518194621 @default.
- W4251819462 hasLocation W42518194622 @default.
- W4251819462 hasLocation W42518194623 @default.
- W4251819462 hasOpenAccess W4251819462 @default.
- W4251819462 hasPrimaryLocation W42518194621 @default.
- W4251819462 hasRelatedWork W1964567729 @default.
- W4251819462 hasRelatedWork W1983576003 @default.
- W4251819462 hasRelatedWork W2061416514 @default.
- W4251819462 hasRelatedWork W2082685970 @default.
- W4251819462 hasRelatedWork W2124872203 @default.
- W4251819462 hasRelatedWork W2169598597 @default.
- W4251819462 hasRelatedWork W2977968290 @default.
- W4251819462 hasRelatedWork W3088178260 @default.
- W4251819462 hasRelatedWork W3126073266 @default.
- W4251819462 hasRelatedWork W4226051264 @default.
- W4251819462 hasVolume "19" @default.
- W4251819462 isParatext "false" @default.
- W4251819462 isRetracted "false" @default.
- W4251819462 workType "article" @default.